Five Prime Therapeutics Announces Timing of Its Fourth Quarter and Full Year 2019 Results Conference Call
February 13 2020 - 4:05PM
Business Wire
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage
biotechnology company focused on developing immune modulators and
precision therapies for solid tumor cancers, will report its fourth
quarter and full year 2019 operational and financial results on
Thursday, February 27, 2020 after the U.S. financial markets close.
Five Prime will also host a conference call and live audio webcast
on Thursday, February 27, 2020 at 4:30 p.m. (ET) / 1:30 p.m. (PT)
to provide a general business update and dicuss the company’s
financial results.
The live audio webcast may be accessed through the "Events &
Presentations" page in the "Investors" section of the company's
website at www.fiveprime.com. Alternatively, participants may dial
(877) 878-2269 (domestic) or (253) 237-1188 (international) and
refer to conference ID: 3872638.
The archived conference call will be available on Five Prime's
website beginning approximately two hours after the event and will
be archived and available for replay for at least 30 days after the
event.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc. develops innovative protein
therapeutics to improve the lives of patients with cancer. Five
Prime’s product candidates have innovative mechanisms of action and
address patient populations in need of better cancer therapies. The
company focuses on developing immuno-oncology and targeted cancer
therapies paired with companion diagnostics to identify patients
who are most likely to benefit from treatment with Five Prime’s
product candidates. Five Prime has entered into strategic
collaborations with leading global pharmaceutical companies and has
promising product candidates in clinical and preclinical
development. For more information, please visit www.fiveprime.com
or follow us on LinkedIn, Twitter and Facebook.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend" and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Five Prime's
expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and
uncertainties. Actual results may differ materially from these
forward-looking statements. Factors that may cause actual results
to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Five Prime’s
filings with the U.S. Securities and Exchange Commission, including
the “Risk Factors” contained therein. Except as required by law,
Five Prime assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
Source: Five Prime Therapeutics, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200213005730/en/
Media and Investor Contact Martin Forrest VP, Investor
Relations & Corporate Communications Five Prime Therapeutics,
Inc. 415-365-5625 martin.forrest@fiveprime.com
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Oct 2023 to Oct 2024